



Life Sciences Licensing

Recognized as a leading life sciences firm, WilmerHale has represented life sciences clients across the United States and the world for more than four decades. In the highly competitive landscape of life sciences, licensing transactions and establishing strategic alliances are critical. Our team helps clients protect their innovations, forge strategic alliances and successfully navigate a complex, dynamic industry. WilmerHale's experienced licensing lawyers shepherd biotech, pharmaceutical, healthcare and medical device clients of all sizes through the complex transactions that make their business possible. Backed by the deep well of knowledge possessed by the firm's patent, tax, antitrust and EU competition lawyers, our transactional lawyers are ready to handle even the most multifaceted matters.

SELECT EXPERIENCE INCLUDES REPRESENTING:

- **Apellis Pharmaceuticals**, a clinical-stage biopharmaceutical company developing therapeutics, in a strategic collaboration with Swedish Orphan Biovitrum AB (Sobi) valued at up to \$1.25 billion to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for the treatment of multiple rare diseases with high unmet need.
- **Arbor Biotechnologies**, developer of genomic tools designed to improve human health and sustainability, in its strategic research collaborations with TCR2 Therapeutics, 4D Molecular Therapeutics and Vertex Pharmaceuticals.
- **Beam Therapeutics**, a biotechnology company developing precision genetic medicines through base editing, in its exclusive, four-year research collaboration with Pfizer.
- **Biogen**, a leading biotechnology company, in its research collaboration with Neomorph Inc., to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological, and immunological diseases for a total consideration of up to \$1.45 billion.
- **Carisma Therapeutics**, a biopharmaceutical company, in a strategic collaboration agreement with Moderna Inc. to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for cancer treatment.

PRACTICE AT A GLANCE

- Handle hundreds of complex strategic alliances, joint ventures, licensing and option transactions, including acquisition option and other M&A forms of technology acquisition transactions
- Significant client base ranging from biotechnology, pharmaceutical, diagnostic and medical device companies at all stages of growth to other key players in the space

- **A privately held biotech research company**, in its exclusive license agreement with Eli Lilly for the development and commercialization of pharmaceutical products to treat immunological and inflammatory diseases.
- **Editas Medicine**, a leading gene editing company, in various strategic collaboration and licensing transaction, including its amended collaboration with Celgene Corporation, now a subsidiary of Bristol-Myers Squibb, to research, develop and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases.
- **Magnet Biomedicine**, a leading biopharmaceutical company, in a collaboration and license agreement with Eli Lilly and Company to discover, develop, and commercialize molecular glue therapeutics in oncology.
- **Mediar Therapeutics**, a clinical-stage biotechnology company, in a global licensing agreement with Eli Lilly and Company to advance MTX-463 into a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF).
- **Medtronic plc.**, a global leader in healthcare technology, in a global partnership with Abbott to collaborate on an integrated continuous glucose monitoring (CGM) sensor.
- **Mersana Therapeutics**, a clinical-stage biopharmaceutical company focused on discovering and developing antibody-drug conjugates, in its global collaboration agreement with GSK.
- **Novo Nordisk**, a multinational pharmaceutical company, in strategic collaborations with Dicerna Pharmaceuticals, Venture Therapeutics and Flagship Pioneering.
- **PTC Therapeutics**, a biopharmaceutical company, in a financing agreement to monetize a portion of the risdiplam royalty stream for \$650 million from Royalty Pharma plc.
- **Ratio Therapeutics**, a pharmaceutical company developing radiopharmaceuticals for cancer treatment, in an exclusive global license and collaboration agreement with Novartis Pharma AG to develop a Somatostatin Receptor 2 radiotherapeutic candidate for cancer.
- **Roche**, a healthcare company, in an exclusive collaboration and licensing agreement with Zealand Pharma to co-develop and co-commercialize petrelintide and combination products for a total consideration of up to \$5.3 billion.
- **Verve Therapeutics**, a biotechnology company pioneering a new approach to the care of cardiovascular disease, in its exclusive, global research collaborations with Vertex Pharmaceuticals and Eli Lilly and Company.
- **Voyager Therapeutics**, a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, in its strategic collaborations with AbbVie, Neurocrine Biosciences, Pfizer, Novartis and Roche.

Guide clients in all aspects of licensing intellectual property and establishing strategic alliances, including:

- Collaboration agreements
- Co-development agreements
- Commercialization agreements
- Material transfer agreements
- Manufacturing and supply agreements
- Clinical trial agreements
- Confidentiality agreements
- Distribution agreements
- University licensing agreements



WilmerHale's life sciences practice has been ranked by *Chambers USA* in the first tier every year since 2008

***LMG Life Sciences* named WilmerHale US Life Cycle Firm of the Year in 2017 and among the shortlist from 2012–2025**

***The Legal 500 US* ranked WilmerHale among the top law firms for life sciences from 2013–2025**

For more information, please contact:

Steven D. Barrett — Partner | +1 617 526 6238 | steven.barrett@wilmerhale.com
Judith Hasko — Partner | +1 650 600 5138 | judith.hasko@wilmerhale.com
Jekkie Kim — Partner | +1 650 600 5133 | jekkie.kim@wilmerhale.com

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 2100 Pennsylvania Avenue, NW, Washington, DC 20037, +1 202 663 6000. Our United Kingdom office is operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers authorized and regulated by the Solicitors Regulation Authority (SRA No. 287488). Our professional rules can be found at www.sra.org.uk/solicitors/standards-regulations/code-conduct-solicitors/. A list of partners and their professional qualifications is available for inspection at our UK office. This material is for general informational purposes only and does not represent our advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all legal developments. Prior results do not guarantee a similar outcome. © 2026 Wilmer Cutler Pickering Hale and Dorr LLP